Cancer chemotherapy: Targeting folic acid synthesis

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 293-301

  Hagner, Nicole ^a   Joerger, Markus ^a  

^a Cantonal Hospital   (Sweden)

Author keywords

Antifolates; Cancer; Folate metabolism; Methotrexate; Molecular pharmacology; Pemetrexed

Indexed keywords

7 HYDROXYMETHOTREXATE; AMINOPTERIN; ANTIRHEUMATIC AGENT; CISPLATIN; CYANOCOBALAMIN; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; EDATREXATE; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; LOMETREXOL; METHOTREXATE; NOLATREXED; PEMETREXED; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PIRITREXIM; PLATINUM; PRALATREXATE; RALTITREXED; TALOTREXIN; THYMIDYLATE SYNTHASE; TRIMETREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHILDHOOD LEUKEMIA; CHORIOCARCINOMA; COLORECTAL CANCER; DNA SYNTHESIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TARGETING; DRUG USE; ENZYME INHIBITION; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAMMAL CELL; MUCOSA INFLAMMATION; OSTEOSARCOMA; PLEURA MESOTHELIOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PSORIASIS; RHEUMATOID ARTHRITIS; SOLID TUMOR; STOMATITIS; T CELL LYMPHOMA; THROMBOCYTOPENIA; VITAMIN METABOLISM;

EID: 79251469453     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: None     Document Type: Article

References (106)

1. Farber S, Cutler EC, Hawkins JW, Harrison JH, Peirce EC 2nd, Lenz GG. The action of pteroylglutamic conjugates on man. Science. 1947; 106(2764):619-621.
2. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238(23):787-793.
3. Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958;259(2):66-74.
4. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-2801.
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901-906.
6. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(8):893-899.
7. Ferreri AJ, Reni M, Dell'Oro S, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology. 2001;60(2):134-140.
8. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40(14):2071-2076.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14): 2636-2644.
10. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
11. Buikhuisen WA, Burgers JA, Vincent AD, et al. Pemetrexed pathwayassociated germline polymorphisms: a useful tool for treatment individualization? J Clin Oncol. 2010;28(27):e482-e483.
12. Chen JS, Chao Y, Bang YJ, et al. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anticancer Drugs. 2010;21(8):777-784.
13. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(12):2038-2045.
14. Ferreri AJ, Guerra E, Regazzi M, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90(2):353-358.
15. Joerger M, Huitema AD, Krahenbuhl S, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer. 2010;102(4):673-677.
16. Zhao R, Matherly LH, Goldman ID. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med. 2009;11:e4.
17. Chen G, Wright JE, Rosowsky A. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol Pharmacol. 1995;48(4): 758-765.
18. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci. 1971; 186:400-422.
19. Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem. 1968;243(19):5007-5017.
20. Whetstine JR, Flatley RM, Matherly LH. The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J. 2002;367(Pt 3):629-640.
21. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994; 73(9):2432-2443.
22. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev. 1999;8(9):775-782.
23. Shen F, Wang H, Zheng X, Ratnam M. Expression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sites. Biochem J. 1997;327(Pt 3):759-764.
24. Shen F, Wu M, Ross JF, Miller D, Ratnam M. Folate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificity. Biochemistry. 1995;34(16): 5660-5665.
25. Ross JF, Wang H, Behm FG, et al. Folate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer. 1999;85(2):348-357.
26. Shen F, Ross JF, Wang X, Ratnam M. Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry. 1994;33(5):1209-1215.
27. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptormediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol Pharmacol. 1995;48(3):459-471.
28. Andrews NC. When is a heme transporter not a heme transporter? When it's a folate transporter. Cell Metab. 2007;5(1):5-6.
29. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006;127(5):917-928.
30. Shayeghi M, Latunde-Dada GO, Oakhill JS, et al. Identification of an intestinal heme transporter. Cell. 2005;122(5):789-801.
31. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003;22(47):7537-7552.
32. Wielinga P, Hooijberg JH, Gunnarsdottir S, et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005;65(10):4425-4430.
33. Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem. 1987;262(28):13520-13526.
34. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun. 1973;52(1):27-34.
35. Curt GA, Jolivet J, Carney DN, et al. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest. 1985;76(4):1323-1329.
36. Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res. 1984;44(8):3190-3195.
37. Rosowsky A, Wright JE, Vaidya CM, Forsch RA. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)- (4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine. Pharmacol Ther. 2000;85(3):191-205.
38. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002;1587(2-3):164-173.
39. Osborn MJ, Freeman M, Huennekens FM. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med. 1958;97(2):429-431.
40. Johnson JM, Meiering EM, Wright JE, Pardo J, Rosowsky A, Wagner G. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Biochemistry. 1997;36(15):4399-4411.
41. Brigle KE, Spinella MJ, Sierra EE, Goldman ID. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem. 1995;270(39):22974-22979.
42. Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem. 2000; 275(40):30855-30863.
43. Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem. 1998;273(46): 30189-30198.
44. Gorlick R, Goker E, Trippett T, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood. 1997;89(3):1013-1018.
45. Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood. 1995;85(2):500-509.
46. Rothem L, Aronheim A, Assaraf YG. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem. 2003; 278(11):8935-8941.
47. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G-.A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000; 70(4):310-315.
48. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100(10):3832-3834.
49. Yang R, Qin J, Hoang BH, Healey JH, Gorlick R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res. 2008;466(9):2046-2051.
50. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79(2):121-126.
51. Hsueh CT, Dolnick BJ. Regulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cells. Biochem Pharmacol. 1994;47(6):1019-1027.
52. Diop-Bove NK, Wu J, Zhao R, Locker J, Goldman ID. Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol Cancer Ther. 2009;8(8):2424-2431.
53. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62(11): 3144-3150.
54. Sirotnak FM, Wendel HG, Bornmann WG, et al. Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin 3705-3712.
55. Bram E, Ifergan I, Shafran A, Berman B, Jansen G, Assaraf YG. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006;58(6):826-834.
56. Shafran A, Ifergan I, Bram E, et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res. 2005;65(18):8414-8422.
57. Gifford AJ, Kavallaris M, Madafiglio J, et al. P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer. 1998;78(2):176-181.
58. Horns RC Jr, Dower WJ, Schimke RT. Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol. 1984;2(1):2-7.
59. Trent JM, Buick RN, Olson S, Horns RC Jr, Schimke RT. Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol. 1984; 2(1):8-15.
60. Li WW, Lin JT, Tong WP, Trippett TM, Brennan MF, Bertino JR. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res. 1992;52(6):1434-1438.
61. Spencer HT, Sorrentino BP, Pui CH, Chunduru SK, Sleep SE, Blakley RL. Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia. 1996;10(3):439-446.
62. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983; 309(18):1094-1104.
63. Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol. 1985;15(2):101-104.
64. Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71-80.
65. Moran RG. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol. 1999;26(2 Suppl 6):24-32.
66. Galivan J, Ryan T, Rhee M, Yao R, Chave K. Glutamyl hydrolase: properties and pharmacologic impact. Semin Oncol. 1999;26(2 Suppl 6): 33-37.
67. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703.
68. von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep. 1977;61(4):745-748.
69. Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol. 2009;63(4): 599-604.
70. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6(4):1322-1327.
71. Maughan T, James R, Kerr D, et al. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimen in the palliative chemotherapy of advanced colorectal cancer (CRC): final results of MRC CRO6 [abstract]. Ann Oncol. 2000; 11 Suppl 4:43.
72. Cunningham D, Zalcberg J, Maroun J, et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. Eur J Cancer. 2002;38(4):478-486.
73. Thomas RJ, Williams M, Garcia-Vargas J. Lessons learned from raltitrexed-quality assurance, patient education and intensive supportive drugs to optimise tolerability. Clin Oncol (R Coll Radiol). 2003;15(5): 227-232.
74. Ford HE, Cunningham D. Safety of raltitrexed. Lancet. 1999;354(9192): 1824-1825.
75. Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet. 2000;39(6):429-443.
76. Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol. 1984;12(1):18-25.
77. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357-4364.
78. Thompson CA. FDA approves pralatrexate for treatment of rare lymphoma. Am J Health Syst Pharm. 2009;66(21):1890.
79. O'Connor O, Pro B, Pinter-Brown L, et al. Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J Clin Oncol. 2009; 27 Suppl 15:449s. Abstract 8561.
80. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev. 2007;26(1):111-128.
81. Ray MS, Muggia FM, Leichman CG, et al. Phase I study of (6R)-5, 10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst. 1993;85(14):1154-1159.
82. Jolivet J, Jansen G, Peters GJ, Pinard MF, Schornagel JH. Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate. Biochem Pharmacol. 1994;47(4):659-665.
83. Grant SC, Kris MG, Young CW, Sirotnak FM. Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest. 1993;11(1):36-45.
84. Kris MG, Kinahan JJ, Gralla RJ, et al. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. Cancer Res. 1988;48(19):5573-5579.
85. Schornagel JH, Verweij J, de Mulder PH, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol. 1995;13(7): 1649-1655.
86. Rosowsky A. PT523 and other aminopterin analogs with a hemiphthaloyl- L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Curr Med Chem. 1999;6(4):329-352.
87. Giles F, Rizzieri DA, George S, et al. A phase I study of talvesta (talotrexin) in relapsed or refractory leukemia or myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts). 2006;108(11):1968.
88. Marshall JL, DeLap RJ. Clinical pharmacokinetics and pharmacology of trimetrexate. Clin Pharmacokinet. 1994;26(3):190-200.
89. Fleming GF, Schilsky RL. Antifolates: the next generation. Semin Oncol. 1992;19(6):707-719.
90. Takimoto CH. New antifolates: pharmacology and clinical applications. Oncologist. 1996;1(1 and 2):68-81.
91. Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MH. Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake. Cancer Res. 1985;45(3): 978-982.
92. Adamson PC, Balis FM, Miser J, et al. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res. 1992; 52(3):521-524.
93. Sakoff JA, Ackland SP. Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase- dependent apoptosis in leukaemia cells. Cancer Chemother Pharmacol. 2000;46(6):477-487.
94. van der Wilt CL, Smid K, Peters GJ. Effects of antifolates on the binding of 5-fluoro-2&-deoxyuridine monophosphate to thymidylate synthase. Biochem Pharmacol. 2002;64(4):669-675.
95. Jhawer M, Rosen L, Dancey J, et al. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007;25(1):85-94.
96. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22(9):1589-1597.
97. Selvaggi G, Scagliotti GV. Histologic subtype in NSCLC: does it matter? Oncology (Williston Park). 2009;23(13):1133-1140.
98. Niyikiza C, Hanauske AR, Rusthoven JJ, et al. Pemetrexed safety and dosing strategy. Semin Oncol. 2002;29(6 Suppl 18):24-29.
99. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol. 2002;29(6 Suppl 18):3-17.
100. Pizzorno G, Moroson BA, Cashmore AR, et al. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res. 1995;55(3): 566-573.
101. Rhee MS, Ryan TJ, Galivan J. Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol. 1999; 44(5):427-432.
102. de Jonge MJ, Punt CJ, Sparreboom A, et al. Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors. J Clin Oncol. 2002;20(7):1923-1931.
103. Calvert AH. Biochemical pharmacology of pemetrexed. Oncology (Williston Park). 2004;18(13 Suppl 8):13-17.
104. Dickgreber NJ, Sorensen JB, Paz-Ares LG, et al. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res. 2010;16(10):2872-2880.
105. Brandes JC, Grossman SA, Ahmad H. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest. 2006;24(3):283-287.
106. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1(7):545-552.